Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data

Journal Publication ResearchOnline@JCU
Harkus, Uasim;Wankell, Miriam;Palamuthusingam, Pranavan;McFarlane, Craig McFarlane;Hebbard, Lionel
Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the world, and for patients with advanced disease there are few therapeutic options available. The complex immunological microenvironment of HCC and the success of immunotherapy in several types of tumours, has raised the prospect of potential benefit for immune based therapies, such as immune checkpoint inhibitors (ICIs), in HCC. This has led to significant breakthrough research, numerous clinical trials and the rapid approval of multiple systemic drugs for HCC by regulatory bodies worldwide. Although some patients responded well to ICIs, many have failed to achieve significant benefit, while others showed unexpected and paradoxical deterioration. The aim of this review is to discuss the pathophysiology of HCC, the tumour microenvironment, key clinical trials evaluating ICIs in HCC, various resistance mechanisms to ICIs, and possible ways to overcome these impediments to improve patient outcomes.

Journal

Seminars in Cancer Biology

Publication Name

N/A

Volume

86

ISBN/ISSN

1096-3650

Edition

N/A

Issue

3

Pages Count

17

Location

N/A

Publisher

Elsevier

Publisher Url

N/A

Publisher Location

N/A

Publish Date

N/A

Url

N/A

Date

N/A

EISSN

N/A

DOI

10.1016/j.semcancer.2022.01.005